Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2025
Reporting Period: Quarter ended September 30, 2025
Business Update: The Company issued a press release on November 13, 2025, providing a business update and announcing financial results for the quarter ended September 30, 2025. This information is incorporated by reference via Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide clear values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a business update and financial results for the quarter ended September 30, 2025, via a press release dated November 13, 2025.
Legal Disclaimer: The information in this filing, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to liabilities under that section, except as expressly set forth by specific reference.
Emerging Growth Company Status: The registrant is an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2025) for specific revenue, profit, and cash flow figures.
- Verify the details of the "business update" mentioned in Item 2.02, as the 8-K text does not elaborate on operational changes.
- Confirm the Company's status as an emerging growth company and any associated accounting standard elections.
- Check the Nasdaq Global Market listings for Common Stock (TLSI) and Warrants (TLSIW) for current trading status.